Phase 2 × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Cyclophosphamide × Clear all
NCT04904588 2026-03-18

ACCESS

Center for International Blood and Marrow Transplant Research

Phase 2 Active not recruiting
300 enrolled
NCT03849651 2026-03-04

TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies

St. Jude Children's Research Hospital

Phase 2 Active not recruiting
69 enrolled 17 charts
NCT04195633 2026-02-27

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Fred Hutchinson Cancer Center

Phase 2 Recruiting
60 enrolled
NCT02861417 2026-02-17

Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
204 enrolled
NCT06001385 2026-02-05

OPTIMIZE

Center for International Blood and Marrow Transplant Research

Phase 2 Active not recruiting
313 enrolled
NCT03674411 2026-01-06

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

Masonic Cancer Center, University of Minnesota

Phase 2 Active not recruiting
22 enrolled 19 charts
NCT01760655 2025-10-30

Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies

Thomas Jefferson University

Phase 2 Completed
62 enrolled 15 charts
NCT05031897 2025-10-30

Two Step Haplo With Radiation Conditioning

Thomas Jefferson University

Phase 2 Recruiting
63 enrolled
NCT03399773 2025-08-26

Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes

Fred Hutchinson Cancer Center

Phase 2 Active not recruiting
31 enrolled
NCT02790515 2025-08-12

Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation

St. Jude Children's Research Hospital

Phase 2 Active not recruiting
170 enrolled
NCT02722668 2025-07-04

UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep

Masonic Cancer Center, University of Minnesota

Phase 2 Completed
15 enrolled 15 charts
NCT03333486 2025-07-04

Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer

Roswell Park Cancer Institute

Phase 2 Terminated
31 enrolled 18 charts
NCT05805605 2025-07-01

Allo HSCT Using RIC and PTCy for Hematological Diseases

Masonic Cancer Center, University of Minnesota

Phase 2 Recruiting
56 enrolled
NCT03246906 2025-06-04

Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

Fred Hutchinson Cancer Center

Phase 2 Terminated
150 enrolled
NCT00719888 2025-03-07

Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease

Fred Hutchinson Cancer Center

Phase 2 Completed
135 enrolled 19 charts
NCT04083170 2025-01-01

Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers

Fred Hutchinson Cancer Center

Phase 2 Terminated
1 enrolled 11 charts
NCT03096782 2023-10-11

Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma

M.D. Anderson Cancer Center

Phase 2 Completed
6 enrolled 10 charts
NCT02661035 2023-09-21

Allo HSCT Using RIC for Hematological Diseases

Masonic Cancer Center, University of Minnesota

Phase 2 Completed
156 enrolled
NCT02556931 2022-11-03

Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
117 enrolled 27 charts
NCT02065154 2022-09-30

Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis

University of Alabama at Birmingham

Phase 2 Completed
39 enrolled 13 charts
NCT00309842 2020-09-10

Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases

Masonic Cancer Center, University of Minnesota

Phase 2 Completed
213 enrolled 19 charts
NCT01010217 2020-03-25

Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide

M.D. Anderson Cancer Center

Phase 2 Completed
176 enrolled 18 charts
NCT00723099 2019-12-27

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

Fred Hutchinson Cancer Center

Phase 2 Completed
73 enrolled 23 charts
NCT02208037 2019-01-23

Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

National Heart, Lung, and Blood Institute (NHLBI)

Phase 2 Completed
279 enrolled 28 charts
NCT02118311 2017-12-02

Treg Cells for AGVHD in Non-myeloablative UCB Transplant

Masonic Cancer Center, University of Minnesota

Phase 2 Withdrawn
NCT00719849 2017-06-14

Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease

Fred Hutchinson Cancer Center

Phase 2 Terminated
13 enrolled 24 charts
NCT02259348 2017-05-30

Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation

St. Jude Children's Research Hospital

Phase 2 Terminated
12 enrolled 12 charts
NCT01621477 2017-02-20

T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant

St. Jude Children's Research Hospital

Phase 2 Terminated
34 enrolled 12 charts
NCT00787761 2012-10-01

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

Northside Hospital, Inc.

Phase 2 Completed
24 enrolled 13 charts